Molecular pathways driving clarithromycin benefit in community-acquired pneumonia analysis of the ACCESS randomised trial
EBioMedicine 2026 Apr 3
6
April, 2026
2
January, 2026
1
July, 2025
29-mRNA host response signatures for classifcation of bacterial infection, viral infection and disease progression in COVID-19 pneumonia: a post hoc analysis of the SAVE-MORE randomized clinical trial
Evdoxia Kyriazopoulou, Antigone Kotsaki, Asimina Safarika, Garyfallia Poulakou, Haralampos Milionis, Simeon Metallidis, Georgios Adamis, Archontoula Fragkou, Aggeliki Rapti, Pierluigi Del Vecchio, Ioannis Kalomenidis, Danae Kitzoglou, Andrea Angheben, Ilias Kainis, Konstantina Iliopoulou, Francesco Saverio Serino, Petros Bakakos, Vassiliki Tzavara, Sofa Ioannou, Lorenzo Dagna, Katerina Dimakou, Glykeria Tzatzagou, Maria Chini, Matteo Bassett, Vasileios Kotsis, George Tsoukalas,
10
January, 2025
Clarithromycin for improved clinical outcomes in community-acquired pneumonia: A subgroup analysis of the ACCESS trial
Karolina Akinosoglou, Konstantinos Leventogiannis, Elisavet Tasouli, Nikolaos Kakavoulis, Georgios Niotis, Sarantia Doulou, Lamprini Skorda, Konstantina Iliopoulou, Anna Papailiou, Paraskevi Katsaounou, Vassiliki Rapti, George Chrysos, Theodoros Seferlis, Styliani Gerakari, Konstantina Dakou, Ilias C. Papanikolaou, Haralampos Milionis, Samantha Kewitz, Sara Georgiadou, Theano Kontopoulou, Vasiliki Tzavara, Antonio Torres, Michael S. Niederman, Evangelos J. Giamarellos-Bourboulis Int
29
November, 2024
HOMI-LUNG CAP
A STRONG CONSORTIUM TO FILL THE GAP Pneumonia is a heart matter too (and viceversa) Connect to the official HOMI-LUNG CAP website Ongoing study Official Study Title A non-interventional, prospective, cross-sectional study of cardiovascular disease progression in survivors of community acquired pneumonia and lung infection by SARS-CoV-2 Brief Description HOMI-LUNG is
25
September, 2024
HEPARIN-BINDING PROTEIN LEVELS PREDICT UNFAVORABLE OUTCOME IN COVID-19 PNEUMONIA: A POST HOC ANALYSIS OF THE SAVE TRIAL
Evdoxia Kyriazopoulou , George N Dalekos, Symeon Metallidis, Garyphalia Poulakou, Ilias C Papanikolaou, Vasiliki Tzavara, Katerina Argyraki, Zoi Alexiou, Periklis Panagopoulos, Michael Samarkos, George Chrysos, Aikaterini Tseliou, Haralampos Milionis, Styliani Sympardi, Anil Vasishta, Evangelos J. Giamarellos-Bourboulis Shock 2024 Mar 1;61(3):395-399. DOI: 10.1097/SHK.0000000000002315View article 🡆 Funding This study was supported in part
13
February, 2024
REACT
Completed study Official Study Title BiomarkeR-guided EArly Clarithromycin Treatment to prevent sepsis progression in community-acquired pneumonia: The REACT Randomized clinical trial Brief Description The primary objective of the REACT RCT is to optimize the clinical benefit from adjunctive clarithromycin treatment shown in the ACCESS trial and to provide evidence for the clinical benefit of
4
January, 2024
Clarithromycin for early anti-inflammatory responses in community-acquired pneumonia in Greece (ACCESS): a randomised, double-blind, placebo-controlled trial
Evangelos J. Giamarellos-Bourboulis, Athanasios Siampanos, Amalia Bolanou, Sarantia Doulou, Nikolaos Kakavoulis, Konstantinos Tsiakos, Sokratis Katopodis, Georgios Schinas, Lamprini Skorda, Zoi Alexiou, Konstantinos Armenis, Paraskevi Katsaounou, George Chrysos, Aikaterini Masgala, Garyphalia Poulakou, Nikolaos Antonakos, Asimina Safarika, Miltiades Kyprianou, Konstantina Dakou, Styliani Gerakari, Ilias C Papanikolaou, Prof Haralampos Milionis, Prof Markos Marangos, Prof George N Dalekos,
10
October, 2022
INSPIRE
Completed study 🡇 Download protocol 🡇 Download SAP Official Study Title Immunotherapy Navigated by Serum Presepsin for Infections of the REspiratory tract: the INSPIRE double-blind, randomized, phase IIa exploratory trial Brief Description The INSPIRE study is an exploratory, randomised, phase IIa clinical trial which aims to evaluate the potential benefit of presepsin-guided anakinra therapy
1
September, 2021
The Role of Macrolides for the Management of Community-Acquired Pneumonia and Pneumonia by the Novel Coronavirus SARS-CoV-2 (COVID-19): A Position Paper by Four Medical Societies from Greece
Evangelos J. Giamarellos-Bourboulis, George L Daikos, Panagiotis Gargalianos, Charalambos Gogos, Marios Lazanas, Periklis Panagopoulos, Garyphallia Poulakou, Helen Sambatakou, Michael Samarkos Infectious Diseases and Therapy 2021 Sep;10(3):1081-1095 DOI: 10.1007/s40121-021-00471-1Download pdf 🡇 Funding The study was funded by the Hellenic Institute for the Study of Sepsis. No Rapid Service Fee was received by the